Status: Recruiting
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
Participants needed: 36
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSUpdated: Jan 28, 2025Locations: 2
Eligibility criteria
Be willing and able to provide written informed consent. [+5]
Patients must have measurable disease by RECIST v 1.1 criteria on CT (or MRI) sc... [+14]